Eli Lilly and Company
) was dealt a legal blow when the judge in the English High Court
ruled in favor of generic player
) in a patent infringement case on its oncology treatment Alimta.
Actavis is looking to sell certain alternative salt forms of Eli
Lilly's therapy in the U.K. and certain other European nations
following the expiry of Alimta compound patents next year.
According to the verdict issued by the court the vitamin dosage
regimen patents related to Alimta would not be infringed by Actavis
in such a scenario.
Further patents on Eli Lilly's Alimta are valid till 2021 in the
U.K. The court ruling also said that Actavis would not infringe
Alimta's vitamin dosage regimen patent prior to the 2021 patent
expiry. The court granted corresponding declarations against Eli
Lilly on vitamin dosage regimen patents related to Alimta in
France, Italy and Spain. Eli Lilly intends to appeal against the
decision. Eli Lilly said that a German court had ruled in its favor
earlier in the year regarding infringement of Alimta's vitamin
dosage regimen patent.
Eli Lilly is facing patent related challenges on Alimta from many
other companies. Alimta, which recorded sales of $632 million (up
2%) in the first quarter of 2014, faces competition from many
) Tarceva in the oncology space.
Eli Lilly, a large cap pharma stock, carries a Zacks Rank #3
(Hold). The company's top line is under pressure due to the
genericization of key products like Zyprexa, Cymbalta and Evista.
Consequently, the pipeline at Eli Lilly must deliver. The company
is also looking to counter the challenge of genericization by
entering into deals/making acquisitions.
) is an example of a better ranked stock in the large cap pharma
space with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ACTAVIS PLC (ACT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Free Stock Analysis
To read this article on Zacks.com click here.